Trial Profile
A Prospective, Randomised, Open-label, Multi-centre Study to Compare Three Chronic Hepatitis B (CHB) Treatment Strategies Over a 2year Period in Chinese HBeAg Positive CHB Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Adefovir (Primary) ; Lamivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms EXPLORE
- 21 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Mar 2010 New trial record